Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STX-100
- Development stage
- Discontinued
- Lead developer
- Biogen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
STX-100 is a humanized monoclonal antibody that targets the integrin alphaVbeta6 (αvβ6) receptor. It was developed as an anti-fibrotic agent, exhibiting significant activity in preclinical models of kidney, lung, and liver fibrosis. The drug’s mechanism involves binding to and inhibiting the function of integrin αvβ6, which plays a key role in activating transforming growth factor-beta (TGF-β), a central mediator of fibrotic processes. By blocking this pathway, STX-100 aims to reduce or prevent tissue fibrosis. The drug was investigated primarily for idiopathic pulmonary fibrosis (IPF) and chronic allograft nephropathy but development has been discontinued following terminated clinical trials[1][4][8].
- Other names
- humanized monoclonal antibody against integrin alphaVbeta6
02
Targets
αVβ6 (Integrin αVβ6)
Beyond the preview
Go deeper on STX-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STX-100.